ADial Pharmaceuticals Promotes Joseph Truluck to Chief Operating and Chief Financial Officer
16155
portfolio_page-template-default,single,single-portfolio_page,postid-16155,bridge-core-2.0.9,ajax_fade,page_not_loaded,,qode-theme-ver-19.6,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,wpb-js-composer js-comp-ver-6.4.1,vc_responsive

ADial Pharmaceuticals Promotes Joseph Truluck to Chief Operating and Chief Financial Officer

Category
News & Media
About This Project

ADial Pharmaceuticals LLC (“ADial”), a developer of pharmaceutical products focused on novel and effective treatments for addictions and related disorders, announced the promotion of Joseph Truluck from Vice President of Operations and Finance to Chief Operating and Chief Financial Officer.

 

Joseph Truluck has served as Vice President of Operations and Finance for ADial since May 2016. Previously, Mr. Truluck served as Vice President of Operations and Finance at Adenosine Therapeutics, LLC. From July 2011 until March 2012, he co-founded and served as Vice President of Operations and Finance for Beonten, Inc., a software development company. Mr. Truluck also served as the Operations Manager of Adenosine Therapeutics’ until its purchase in August 2008 by Clinical Data. Mr. Truluck has an MBA from Tulane University with a concentration in Finance and a Masters in Philosophy at the University of Virginia.

 

William Stilley, Chief Executive Officer of ADial Pharmaceuticals, stated, “Since joining ADial Pharmaceuticals, Joe has done a tremdous job strengthening the financial and operational infrastructure that will be necessary as we embark on the next phase of our growth, including initiation of our phase 3 trials.”

 

Mr. Truluck commented, “I am thrilled to accept this new role at such an exciting time in the Company’s development. In the U.S. alone, approximately 35 million people are estimated to have Alcohol Use Disorder. Current therapies are often ineffective, as they require abstinence prior to initiating therapy. AD04 is genetically targeted to the approximately one-third of patients that have the genetic biomarker that appears to identify patients that will respond to the drug. Additionally, it is unique because the treamtnet goal is to reduce risk drinking. We are encouraged by the results of the Phase 2b trial, which included 283 patients, and we look forward to now advancing our clinical activities into Phase 3.”